This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Events OverviewITM Precision Oncology Symposium 2022ITM's Symposium at NuklearMedizin 20222nd ICPO Forum for Theranostics in Precision OncologyITM's ESMO 2021 Industry Satellite SymposiumITM Precision Oncology Symposium 2021COMPETE e-poster at AACR 2021

ITM's Symposium at NuklearMedizin 2022

Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective

On behalf of ITM I would like to invite you to our NulkearMedizin 2022 Symposium “Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective” on Thursday, 28. April 2022, 12:30 - 13:30 pm, room 2 at the Leipzig Congress Centre.

Our symposium will be chaired by Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, and the faculty will consist of Prof. Dr. Wolfgang Wadsak, Head of Medicinal Radiochemistry and Biomarker Development, Medical University of Vienna, and Neil Quigley, Global Product Manager, ITM.

The in-house preparation of radiopharmaceuticals has resulted in major developments in the field of nuclear medicine and precision oncology, including the development of prostate cancer and neuroendocrine tumor treatment. The symposium will provide an introduction and overview of the current status of in-house preparation with some recent developments that can be attributed to it.

I look forward to you joining us in what promises to be an exciting overview of recent developments and radiopharmacy perspective with critical analysis of the latest science and clinical practice that is driving the Targeted Radionuclide Therapy paradigm into the forefront of patient management.

Steffen Schuster, CEO ITM

 

Program


Chair: Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, Munich
 

Recent Developments: New Targets and Emerging 225Ac-Therapies
Neil Quigley, Global Product Manager, ITM, Munich

Die Herstellung von Radiopharmaka zur unmittelbaren Anwendung – essentieller Baustein und Innovationstreiber in der Nuklearmedizin
Prof. Wolfgang Wadsak, Leiter der Medizinischen Radiochemie und Biomarkerentwicklung der klinischen Abteilung für Nuklearmedizin, Universitätsklinikum AKH Wien

Serving Future Global Demand of n.c.a. 177Lu and Development of 225Ac
Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, Munich

Q&A Session

 

Program for Download

NulearMedizin 2022 Congress Website